Additionally, ongoing clinical trials of weekly GLP-1 RAs in NAFLD will provide further clarity on the safety and efficacy of this treatment, potentially solidifying the position of GLP-1 RAs in the clinical management of NAFLD/NASH. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.